Short answer · Medically reviewed summary · Last updated: 2026-04-06
Stevens Johnson Syndrome was first described in the medical literature in 1922 by American pediatricians Albert Mason Stevens and Frank Chambliss Johnson, who identified it as a distinct, severe eruptive fever in two children characterized by mucosal lesions and ophthalmic involvement. From Clinical Observation to Modern Understanding Initially, Stevens and Johnson believed the condition they observed was a unique form of erythema multiforme. For decades, the medical community struggled to differentiate Stevens Johnson Syndrome from other severe skin reactions.
2 people with Stevens Johnson Syndrome have shared their first-person experience on this question at DiseaseMaps.
What is the history of Stevens Johnson Syndrome?
History of Stevens Johnson Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
Stevens Johnson Syndrome was first described in the medical literature in 1922 by American pediatricians Albert Mason Stevens and Frank Chambliss Johnson, who identified it as a distinct, severe eruptive fever in two children characterized by mucosal lesions and ophthalmic involvement.
From Clinical Observation to Modern Understanding
Initially, Stevens and Johnson believed the condition they observed was a unique form of erythema multiforme. For decades, the medical community struggled to differentiate Stevens Johnson Syndrome from other severe skin reactions. It was not until the mid-20th century that researchers began to recognize that Stevens Johnson Syndrome was frequently a drug-induced hypersensitivity reaction rather than an idiopathic infection.
Evolution of Treatment and Genetic Insights
Historically, treatment for Stevens Johnson Syndrome was largely supportive, focusing on wound care and fluid management. A major shift occurred in the late 20th century with the understanding of the role of the immune system in the disease's pathogenesis. The discovery of specific human leukocyte antigen (HLA) alleles, such as HLA-B*15:02, revolutionized our understanding of why certain populations are at higher risk for Stevens Johnson Syndrome when exposed to specific medications like carbamazepine or allopurinol. This genetic breakthrough has moved medicine toward a model of preventative pharmacogenomics.
Advocacy and Awareness
The patient experience has historically been fraught with isolation due to the sudden and traumatic nature of the illness. Over the last few decades, patient advocacy groups have been instrumental in pushing for earlier recognition and standardized protocols. By sharing their lived experiences, the Stevens Johnson Syndrome community has helped shift the clinical focus toward long-term survivorship, particularly regarding the chronic ocular and dermatological sequelae that follow the acute phase of the disease.
Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: Rare Disease Information Portal
- Online Mendelian Inheritance in Man (OMIM)
- Stevens-Johnson Syndrome Foundation
Posted Oct 4, 2017 by Yolika 2000
Posted Oct 16, 2017 by Karen 3550
